TTY Biopharm (4105) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT
9.1B, trading at NT$77.00 on the TWO. This SniperIQ fundamentals page covers TTY Biopharm's valuation (P/E 11.9x, P/B 3.1x), profitability (net margin 25.1%), revenue (NT$6.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
9.1B
P/E (TTM)11.9x
Net Margin25.1%
Revenue (FY25)NT$6.5B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is TTY Biopharm's market cap?
TTY Biopharm (4105) has a market capitalization of approximately NT
9.1B, trading at NT$77.00 on the TWO. Market cap moves with the live share price.
What is TTY Biopharm's P/E ratio?
TTY Biopharm's trailing twelve-month P/E ratio is 11.9x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TTY Biopharm?
TTY Biopharm runs a net profit margin of 25.1%, a gross margin of 57.4%, and an operating margin of 27.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TTY Biopharm generate?
TTY Biopharm reported revenue of NT$6.5B for fiscal year 2025, with net income of NT
.6B and earnings per share (EPS) of 6.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TTY Biopharm pay a dividend?
TTY Biopharm offers a trailing dividend yield of about 5.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is TTY Biopharm financially healthy?
TTY Biopharm carries a debt-to-equity ratio of 0.16x and a current ratio of 1.71x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TTY Biopharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TTY Biopharm (4105) the key facts are: market cap NT
9.1B, P/E 11.9x, revenue NT$6.5B, 52-week range 71.6-87. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TTY Biopharm's full fundamentals live
Get TTY Biopharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.